Dexmedetomidine Sublingual Film: A New Treatment to Reduce Agitation in Schizophrenia and Bipolar Disorders

Author:

Karlin Danielle M.1,Nelson Leigh Anne1ORCID,Campbell Austin R.2

Affiliation:

1. Department of Pharmacy, School of Pharmacy, University of Missouri–Kansas City, Kansas City, MO, USA

2. Department of Pharmacy, School of Pharmacy at MU, University of Missouri–Kansas City, Columbia, MO, USA

Abstract

Objective: The objective of this study was to review the available literature for dexmedetomidine sublingual film use in the treatment of acute agitation associated with schizophrenia and bipolar disorders. Data Sources: A literature search of PubMed (January 2017-March 2023) and EMBASE (January 2017-March 2023) was performed using the terms: Igalmi, dexmedetomidine, schizophrenia, bipolar disorder, and agitation. Additional information sources include ClinicalTrials.gov, scientific posters, and articles identified through review of references from clinical trials publications. Study Selection and Data Extraction: Relevant English-language articles conducted in humans were considered, with a preference for phase 3 clinical trials. Trial analyses and articles discussing pharmacology, pharmacokinetics, efficacy, and safety were also evaluated. Data Synthesis: Dexmedetomidine sublingual film was evaluated for use in schizophrenia in the SERENITY 1 pivotal trial and for bipolar disorders in the SERENITY 2 pivotal trial. Both studies found treatment of mild to moderate agitation with dexmedetomidine sublingual film 180 and 120 μg to be superior to placebo in reducing the severity of agitation. Treatment effect was seen as early as 20 minutes. Somnolence was the most common adverse effect in both studies. Cardiovascular adverse effects were mild and transient in most cases. Relevance to Patient Care and Clinical Practice: Dexmedetomidine sublingual film is a new and novel treatment for agitation and gives clinicians an alternative to antipsychotic and benzodiazepine use. It has advantageous properties including its noninvasive route of administration, fast absorption, and rapid onset of effect. Cost may limit its use. Conclusion: Dexmedetomidine sublingual film provides an alternative approach to treatment of acute agitation in adults with schizophrenia and bipolar disorders based on both mechanism of action and route of administration.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Reference26 articles.

1. Precedex (dexmedetomidine hydrochloride). Lake Forest, IL: Hospira, Inc. 2022.

2. Igalmi (dexmedetomidine). New Haven, CT: BioXcel Therapeutics, Inc. 2022.

3. Diagnostic and Statistical Manual of Mental Disorders

4. American Psychological Association. Published 2022. https://www.apa.org/pi/about/publications/caregivers/practice-settings/assessment/tools/cohen-mansfield#:~:text=Description%20of%20Measure%3A%20The%20Cohen

5. Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3